Beqvez (fidanacogene elaparvovec)
pCPA File Number:
22602
Negotiation Status:
Under consideration for negotiation
Indication(s):
Treatment of adults (aged 18 years or older) with moderately severe to severe Hemophilia B (congenital Factor IX deficiency) who are negative for neutralizing antibodies to variant AAV serotype Rh74
Sponsor/Manufacturer:
Pfizer Canada ULC
CADTH Project Number:
SG0802-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable